A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

Novo Nordisk has announced that it will stop producing its insulin product, Levemir, after the end of 2024. Eli Lilly is also reducing its production volume of its insulin product, Humalog.

Meanwhile Novo Nordisk has also seen its ranking surge ... strong performances from GLP-1 analogue Victoza, insulin analogue Levemir and the 2015 launch of longer-acting insulin analogue Tresiba.

Novo Nordisk A/S NVO reported fourth-quarter ... Sales of long-acting insulins (Tresiba, Xultophy, Levemir and Awiqli) jumped 40% in the fourth quarter. Ozempic, which has witnessed a strong ...

Levemir (insulin detemir) is safe to receive while pregnant or breastfeeding. However, factors such as the form you get or the condition the drug helps treat may determine whether you should ...

Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight ...

Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet ...